<SEC-DOCUMENT>0001437749-22-008615.txt : 20220408
<SEC-HEADER>0001437749-22-008615.hdr.sgml : 20220408
<ACCEPTANCE-DATETIME>20220408170509
ACCESSION NUMBER:		0001437749-22-008615
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220408
DATE AS OF CHANGE:		20220408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		22817773

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>dffn20220408_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head>
	<title>dffn20220408_defa14a.htm</title>

	<!-- Generated by ThunderDome Portal - 4/8/2022 5:51:31 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b>FORM 8-K</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Date of Report (Date of earliest event reported): April 7, 2022</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 20pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:33.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number)</p>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>300 East Main Street, Suite 201</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align: bottom; width: 50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>22902</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(434) 220-0718</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; vertical-align: top; width: 42.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of each class</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; border-right: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Trading Symbol(s)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33.7%; border-right: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 42.8%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">DFFN</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</b>&#167;&#8201;<b>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</b>&#167;&#8201;<b>240.12b-2 of this chapter).</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Emerging growth company</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01 Other Events.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 7, 2022, pursuant to Section 2.14 of the Bylaws, as amended, of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;), the Company&#8217;s board of directors determined to postpone the Company&#8217;s upcoming Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;) from the previously scheduled date of Thursday, April 14, 2022. The postponement is intended to provide additional time to the Company&#8217;s stockholders to consider and vote on the proposals to be acted upon at the Special Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Special Meeting will now be held on Monday, April 18, 2022, at 9:00 a.m. ET. The Special Meeting will still be completely virtual, the record date for the meeting remains March 24, 2022, and there is no change to the purpose of the Special Meeting or any of the proposals to be acted upon at the Special Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 8, 2022, the Company issued a press release announcing the new date of the Special Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Important Information About the Special Meeting of Stockholders and Where to Find It</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Special Meeting, the Company has filed a definitive proxy statement, dated March 28, 2022 (as amended and supplemented, the &#8220;Proxy Statement&#8221;) with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The Proxy Statement and certain other materials related to the Special Meeting have also been made available to the stockholders of the Company. The Company&#8217;s stockholders are advised to read the Proxy Statement and any supplements or amendments thereto, as these materials contain important information about Diffusion and the matters subject to approval at the Special Meeting. Stockholders may obtain copies of the Proxy Statement and other documents filed with the SEC, without charge, at the SEC&#8217;s website at <u>www.sec.gov</u>, or by directing a request to: Diffusion Pharmaceuticals Inc., 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, Attn: General Counsel or via e-mail to <u>proxyrequests@diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Participants in Solicitation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company, its directors, and its executive officers may solicit proxies with respect to the Special Meeting in person, by telephone, or by other means of communication. Accordingly, the Company, its directors, and its executive officers may be deemed to be participants in the solicitation of proxies in respect of the Special Meeting. Certain information concerning the Company, its directors, and its executive officers is set forth in the Proxy Statement. No additional compensation will be paid to any director or executive officer for any such solicitation of proxies and the Company&#8217;s directors and officers have no substantial interests, directly or indirectly, in the matters to be acted upon at the Special Meeting, except to the extent of their ownership of shares of the Company&#8217;s stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&nbsp;<b>9.01</b>&nbsp;&#8211;&nbsp;<b>Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(d) Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Number</b></p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_356623.htm" style="-sec-extract:exhibit;">Press Release, issued April 8, 2022, Announcing New Date for Previously Announced Special Meeting of Stockholders</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: April 8, 2022</p>
			</td>
			<td colspan="2" style="width: 4%;" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 34%;" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 4%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 34%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Name:</p>
			</td>
			<td style="width: 34%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">William Elder</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:</p>
			</td>
			<td style="width: 34%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">General Counsel &amp; Corporate Secretary</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_356623.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_356623.htm</title>

	<!-- Generated by ThunderDome Portal - 4/8/2022 5:50:18 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px">&nbsp;</p>

<p style="margin: 0pt; text-align: left;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="image2.jpg" src="image2.jpg"></p>

<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Diffusion Pharmaceuticals Announces New Date for </b></p>

<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Previously Announced Special Meeting of Stockholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 18pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 36pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><i>No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHARLOTTESVILLE, Va., April 8, 2022 --&nbsp;<b>Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)</b>&nbsp;(&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, today announced a postponement of its Special Meeting of Stockholders previously scheduled to be held on Thursday, April 14, 2022 at 9:00 a.m. ET (the &#8220;Special Meeting&#8221;). The postponement is intended to provide additional time to the Company&#8217;s stockholders to consider and vote on the proposals to be acted upon at the Special Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Special Meeting will now be held on Monday, April 18, 2022, at 9:00 a.m. ET. The Special Meeting will still be completely virtual, the record date for the meeting remains March 24, 2022, and there is no change to the purpose of the Special Meeting or any of the proposals to be acted upon at the Special Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders who have not yet voted are encouraged to do so. Stockholders that own their shares in &#8220;street name&#8221; through a stock brokerage account or through a bank or nominee should consult the broker, bank, or nominee about its procedures to vote the shares. Valid proxies that have already been submitted will continue to be valid for purposes of the Special Meeting and at all adjournments or postponements thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Important Information About the Special Meeting of Stockholders and Where to Find It</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Special Meeting, Diffusion has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The definitive proxy statement and certain other materials related to the Special Meeting have also been made available to the stockholders of the Company. The Company&#8217;s stockholders are advised to read the definitive proxy statement and any supplements or amendments thereto (including any supplement or amendment filed in connection with this postponement of the Special Meeting), as these materials contain important information about Diffusion and the matters subject to approval at the Special Meeting. Stockholders may obtain copies of the definitive proxy statement and other documents filed with the SEC, without charge, at the SEC&#8217;s web site at <u>www.sec.gov</u>, or by directing a request to: Diffusion Pharmaceuticals Inc., 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, Attn: General Counsel or via e-mail to <u>proxyrequests@diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions, including hypoxic solid tumors. For more information, please visit us at <u>www.diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="image2.jpg" src="image2.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company&#8217;s upcoming Special Meeting and the matters to be acted upon thereat. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, the Company&#8217;s ability to achieve the presence of a quorum of stockholders entitled to vote at the Special Meeting, the results of the stockholder vote on each proposal submitted for approval at the Special Meeting, the Company&#8217;s ability to maintain compliance with the continued listing standards of Nasdaq, general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors:</b>&nbsp;&nbsp;<br>
<u>Tiberend Strategic Advisors, Inc.&nbsp;</u><br>
Lisa Sher/Daniel Kontoh-Boateng<br>
<u>lsher@tiberend.com</u>&nbsp;/&nbsp;<u>dboateng@tiberend.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b>&nbsp;&nbsp;<br>
Kate Barrette<br>
RooneyPartners&nbsp;&nbsp;<br>
<u>Kbarrette@rooneypartners.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ !@$2  ,
M   !  $   ,!  4    !    5@,#  $    !     %$0  $    ! 0   %$1
M  0    !   .PU$2  0    !   .PP       8:@  "QC__; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $T
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M'[97[+=O^Q9_P;M^+/AC!-%<R^%?"$4-Y<1#Y+F[>[BFN9%SSM:>20C/."*
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MPWX@^&FKR76BWJV89)M/O8&GFE@G20PN"LK"2*0D;64BO0/BC_P4U\7>!?\
M@D]\'OC_ &N@^'9O$OQ&3P>U[IT@F^PVQUF>TCG\H!]_R"X;9ECR!G=S71?
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MG-Q<VA^S6TZ75LLKNT9!CD^8AB1@CZD^"T/Q=B^+_P 3G\?77@:?P-)J-L?
M*:(EPNHQ6?D?Z1]O,GR&3S<%?+R,;N@*@ 'J%%"G(HH **** "C%%% !M]J*
M** #%%%% !1C-%% !BC;[444 &*,<T44 %&*** #%!&:** #%%%% !BC'-%%
..  !@48HHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
